Micromet, Inc.
http://www.micromet.de
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Micromet, Inc.
Beam And Verve Benefit From Buzz Around Base-Editing Therapies
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.
Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds
Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns.
EU Approvals Beckon For Inrebic & Novel Adalimumab Biosimilar
Inrebic, Celgene’s myelofibrosis treatment, and Yuflyma, Celltrion’s high-concentration adalimumab biosimilar, are among the latest new drugs that have been recommended for approval for use across the EU. Meanwhile, TETEC has withdrawn its EU marketing application for Artobend.
Company Information
- Other Names / Subsidiaries
-
- CancerVax Corporation